TAVI: Mobility Predicts Outcomes

Original Title: Poor Mobility Predicts Adverse Outcomes Better Than Other Frailty Indices in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: James Cockburn, et al. Catheterization and Cardiovascular Intervention 2015;86:1271-1277 Courtesy of Dr. Carlos Fava Interventional Cardiologist Favaloro Foudation – Buenos Aires There is a group of high risk patients that are also fragile, and there is<a href="https://solaci.org/en/2015/12/17/tavi-mobility-predicts-outcomes/" title="Read more" >...</a>

TAVI in patients older than 90: similar outcomes to those obtained in younger patients

Original title: Comparison of Outcomes of Transcathether Aortic Valve Implantation in Patients ≥90 Years Versus <90 Years. Reference: Yigal Abramowitz, et al. Am J Cardiol 2015;116:1110-1115. More and more 90 year old patients require transcatheter aortic valve replacement (TAVI); however, its benefits have not been studied in this particular population. This study enrolled 734 patients<a href="https://solaci.org/en/2015/11/16/tavi-in-patients-older-than-90-similar-outcomes-to-those-obtained-in-younger-patients/" title="Read more" >...</a>

NOTION: TAVR in low-risk patients

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used<a href="https://solaci.org/en/2015/06/24/notion-tavr-in-low-risk-patients/" title="Read more" >...</a>

PARTNER to 5 years. TAVR is an effective alternative to surgery in high risk patients

This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up<a href="https://solaci.org/en/2015/06/24/partner-to-5-years-tavr-is-an-effective-alternative-to-surgery-in-high-risk-patients/" title="Read more" >...</a>

PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>

Transfemoral TAVI under local anesthesia with similar results to general anesthesia

Original title: Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry. Reference: Oguri A et al. CircCardiovascInterv. 2014; 7:602-610.   Transcatheter aortic valve replacement (TAVI) performed under local anesthesia is becoming an increasingly common procedure. This study compared clinical outcomes in patients<a href="https://solaci.org/en/2014/11/12/transfemoral-tavi-under-local-anesthesia-with-similar-results-to-general-anesthesia/" title="Read more" >...</a>

TAVR: Regression of Left Ventricular Hypertrophy Decreases Re-hospitalization

Original title: Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization. Reference: Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73.   Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/tavr-regression-of-left-ventricular-hypertrophy-decreases-re-hospitalization/" title="Read more" >...</a>

Fully percutaneous vs. surgical transfemoral TAVR: similar major vascular complications rate and shorter hospital stay.

Original title: Factors associated with vascular complications in patients undergoing balloon-expandable transfemoral transcatheter aortic valve replacement via open versus percutaneous approaches. Reference: Kadakia MB et al. Circ Cardiovasc Interv. 2014; Epub ahead of print.   This retrospective study included 331 patients undergoing transfemoral TAVR in one center between 2007 and 2013. 64% of the population were treated with<a href="https://solaci.org/en/2014/07/28/fully-percutaneous-vs-surgical-transfemoral-tavr-similar-major-vascular-complications-rate-and-shorter-hospital-stay/" title="Read more" >...</a>

TVAR live edited broadcasts are safe.

Original title: The impact of live transmition on patients outcomes during transcatheter aortic valve replacement: Results fron the VERITAS study. Reference: Ron Waskman, et al. Cardiovascular Revascularization Medicine 2014;15:63-68   With the advancement of medical technology and the great development of telecommunications, performing live or edited cases has become a common occurrence in medical education, but one of<a href="https://solaci.org/en/2014/04/11/tvar-live-edited-broadcasts-are-safe/" title="Read more" >...</a>

Low flow impact on outcomes following TAVI should be taken into account

Original title: Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Reference: Florent Le Ven, et al. J Am Coll Cardiol 62;9:792-788 A study of low flow (SVi <35ml/m2) in the context of severe aortic stenosis has shown it is a predictor of worse outcomes after surgery, even though evolution with medical<a href="https://solaci.org/en/2013/08/26/low-flow-impact-on-outcomes-following-tavi-should-be-taken-into-account/" title="Read more" >...</a>